Motif Bio Follow Verify

www.motifbio.com
Motif Bio PLC
Type	Public
Industry	Biopharmaceuticals
Founded	2014
Headquarters	London, United Kingdom
Key people	Graham George Lumsden (CEO), David B. Huang (Chief Medical Officer), Robert Joseph Bertoldi
Number of employees	4

We are a clinical stage biopharmaceutical company engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalized patients caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus and multi-drug resistant streptococcus pneumoniae.

Products

Iclaprim is a dihydrofolate reductase (DHFR) inhibitor originally discovered by F. Hoffman-La Roche Ltd. Iclaprim was licensed to and developed by Arpida AG.
Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics, including trimethoprim. Iclaprim exhibits potent activity against Gram-positive clinical isolates of many genera of staphylococci, including methicillin sensitive staphylococci (MSSA) and methicillin resistant staphylococci (MRSA).

Top 5 Recent Tweets

Date	Author	Comment
April 09, 2023	WmMorrisSocUK	Happy Easter! 🐤 In celebration of Easter we are sharing this unique pencil and watercolour design attributed to Joh… https://t.co/y0yy7AuCGg

Top 5 Lifetime News Headlines

Top Authors

• Archana Sinha
• Napaporn Panomrit
• View all authors

Verification history

• 2,803 days ago


• View all verifications